Strategic Exits As a nimble holding company with a track record of building and exiting portfolio companies to public firms, Franklin Group represents a ready made platform for strategic buyers seeking bolt on acquisitions in nascent, regulated biotechnologies.

Regulatory Expertise The focus on industries with developing regulations creates a sales angle for regulatory consulting, due diligence support, and licensing partnerships that can de risk market entry for portfolio assets.

Cannabis Market Link Historical links to cannabis related assets suggest a potential entry point for cannabis operators and adjacent biotech firms seeking research and development capabilities and regulatory navigation for product development.

Lean Regional Presence Based in Denver with a small team and limited operations after 2022, Franklin Group can offer co investment or advisory opportunities to regional CROs, biotech startups, and university affiliated labs looking for capital and strategic backing.

Growth Financing Fit Revenue in the low single digit millions with modest funding indicates opportunities for growth stage investors and larger life sciences buyers to participate in a staged partnership or platform roll up.